Ignite Creation Date:
2024-05-06 @ 8:15 PM
Last Modification Date:
2024-10-26 @ 3:23 PM
Study NCT ID:
NCT06307457
Status:
COMPLETED
Last Update Posted:
2024-05-02
First Post:
2024-03-05
Brief Title:
A Study of HRHER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark
Sponsor:
Pfizer
Organization:
Pfizer
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Breast Cancer |
Keywords:
| Name | View |
|---|---|
| Metastatic Breast Cancer mBC | View |
| ICD10 C50 | View |
| Advanced Breast Cancer | View |
| HRHER2- | View |
| Hormone receptor positive Human Epidermal growth factor Receptor 2 negative | View |
| Endocrine sensitive | View |
| Endocrine resistant | View |
| de novo mBC | View |
| Denmark | View |
| Danish Breast Cancer Group DBCG | View |
| Palbociclib | View |
| Aromatase Inhibitor AI | View |
| Real-World Evidence RWE | View |
| Non-Interventional Study NIS | View |
| Age | View |
| Comorbidities | View |
| First-line Treatment | View |
| Charlson Comorbidity Index CCI | View |